ATE246681T1 - Sulfonamide - Google Patents

Sulfonamide

Info

Publication number
ATE246681T1
ATE246681T1 AT95941706T AT95941706T ATE246681T1 AT E246681 T1 ATE246681 T1 AT E246681T1 AT 95941706 T AT95941706 T AT 95941706T AT 95941706 T AT95941706 T AT 95941706T AT E246681 T1 ATE246681 T1 AT E246681T1
Authority
AT
Austria
Prior art keywords
pct
sec
compounds
date
endothelin
Prior art date
Application number
AT95941706T
Other languages
German (de)
English (en)
Inventor
Volker Breu
Kaspar Burri
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loeffler
Marcel Mueller
Werner Neidhart
Henri Ramuz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE246681T1 publication Critical patent/ATE246681T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69Benzenesulfonamido-pyrimidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Steroid Compounds (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT95941706T 1994-12-20 1995-12-08 Sulfonamide ATE246681T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH383794 1994-12-20
CH241995 1995-08-24
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides

Publications (1)

Publication Number Publication Date
ATE246681T1 true ATE246681T1 (de) 2003-08-15

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941706T ATE246681T1 (de) 1994-12-20 1995-12-08 Sulfonamide

Country Status (25)

Country Link
US (1) US6004965A (Direct)
EP (1) EP0799209B1 (Direct)
JP (1) JP2989014B2 (Direct)
KR (1) KR100445085B1 (Direct)
CN (1) CN1098254C (Direct)
AT (1) ATE246681T1 (Direct)
AU (1) AU701767B2 (Direct)
BR (1) BR9510104A (Direct)
CA (1) CA2208018C (Direct)
CY (1) CY2495B1 (Direct)
CZ (1) CZ287916B6 (Direct)
DE (1) DE69531457T2 (Direct)
DK (1) DK0799209T3 (Direct)
ES (1) ES2203649T3 (Direct)
FI (1) FI120397B (Direct)
HU (1) HU228619B1 (Direct)
IL (1) IL116385A (Direct)
MA (1) MA23744A1 (Direct)
MY (1) MY131126A (Direct)
NO (1) NO316645B1 (Direct)
NZ (1) NZ297797A (Direct)
PT (1) PT799209E (Direct)
SA (1) SA95160421B1 (Direct)
TW (1) TW313568B (Direct)
WO (1) WO1996019459A1 (Direct)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
ATE267808T1 (de) * 1997-08-19 2004-06-15 Hoffmann La Roche Verfahren zur herstellung von 2,5- disubstituierten pyridinen
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ATE311382T1 (de) * 1998-08-10 2005-12-15 Verfahren zur herstellung von 2-carbamoyl- pyridinen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
NZ512526A (en) * 1999-09-03 2004-01-30 Actelion Pharmaceuticals Ltd 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
KR20020068373A (ko) * 1999-12-22 2002-08-27 액테리온 파마슈티칼 리미티드 부틴 디올 유도체
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1580188B9 (en) 2002-02-11 2012-05-23 Bayer HealthCare, LLC Aryl ureas as kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CA2507334C (en) 2002-12-02 2013-05-07 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
CN102816113B (zh) 2003-07-23 2015-05-13 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US20080161321A1 (en) 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
AU2008219065B2 (en) 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
ATE550333T1 (de) 2007-11-05 2012-04-15 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose
PL2229356T3 (pl) 2007-12-03 2012-03-30 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
CN102459247B (zh) 2009-05-15 2014-09-17 诺华股份有限公司 作为醛固酮合酶抑制剂的苯并噁唑酮衍生物
KR101338555B1 (ko) 2009-05-15 2013-12-09 노파르티스 아게 알도스테론 신타제 억제제로서의 아릴 피리딘
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
BRPI1015069A2 (pt) 2009-05-28 2019-09-24 Novartis Ag compostos derivados de aminobutíricos substituidos como inibidores de neprilisina, uso dos mesmos, composição farmacêutica, combinação e método para inibição de atividade endopeptidase neutra.
EP2501678B1 (en) 2009-11-17 2015-09-23 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
MX342912B (es) 2010-04-15 2016-10-19 Marine Polymer Tech Inc Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2817415C (en) 2010-11-24 2020-05-12 Lexicon Pharmaceuticals, Inc. Antibodies that bind notum pectinacetylesterase
US20140127310A1 (en) 2011-04-15 2014-05-08 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
RS57358B1 (sr) 2013-02-14 2018-08-31 Novartis Ag Supstituisani derivati bisfenilbutanoil fosfonske kiseline kao inhibitori nep (neutralne endopeptidaze)
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
SG11201600208RA (en) 2013-07-25 2016-02-26 Novartis Ag Bioconjugates of synthetic apelin polypeptides
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化(瑞士)有限公司 新的經吡啶及經嘧啶取代之三uv吸收劑
CA3197265A1 (en) * 2020-11-05 2022-05-12 Timo Rager A stable crystalline hydrate of clazosentan disodium salt
KR20240121242A (ko) 2021-12-17 2024-08-08 넥세라 파마 씨오., 엘티디. 클라조센탄 디소듐 염, 이의 제조 및 이를 포함하는 약학 조성물
US20250228835A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines and related compounds and their use in treating medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (Direct) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (Direct) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI972628L (fi) 1997-06-18
DE69531457T2 (de) 2004-06-24
DK0799209T3 (da) 2003-11-24
MX9704587A (es) 1998-07-31
IL116385A0 (en) 1996-03-31
MY131126A (en) 2007-07-31
EP0799209B1 (en) 2003-08-06
US6004965A (en) 1999-12-21
CZ287916B6 (cs) 2001-03-14
JPH10509182A (ja) 1998-09-08
FI972628A0 (fi) 1997-06-18
CY2495B1 (en) 2005-09-02
FI120397B (fi) 2009-10-15
PT799209E (pt) 2003-12-31
WO1996019459A1 (en) 1996-06-27
SA95160421B1 (ar) 2006-05-01
JP2989014B2 (ja) 1999-12-13
MA23744A1 (fr) 1996-07-01
EP0799209A1 (en) 1997-10-08
NZ297797A (en) 1999-10-28
BR9510104A (pt) 1997-11-25
CN1098254C (zh) 2003-01-08
NO972538L (no) 1997-06-04
NO316645B1 (no) 2004-03-22
AU701767B2 (en) 1999-02-04
DE69531457D1 (en) 2003-09-11
TW313568B (Direct) 1997-08-21
NO972538D0 (no) 1997-06-04
KR100445085B1 (ko) 2004-10-14
CZ187497A3 (en) 1997-10-15
ES2203649T3 (es) 2004-04-16
CN1170407A (zh) 1998-01-14
HU228619B1 (en) 2013-04-29
AU4304196A (en) 1996-07-10
CA2208018C (en) 2007-03-27
HK1001973A1 (en) 1998-07-24
IL116385A (en) 2000-07-16
CA2208018A1 (en) 1996-06-27
HUT77884A (hu) 1998-09-28

Similar Documents

Publication Publication Date Title
ATE246681T1 (de) Sulfonamide
BR9407239A (pt) Azadioxacicloalquenos substituídos
DZ1794A1 (fr) Nouvelle formule pharmaceutique.
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
ATE196765T1 (de) Dihydrobenzofurane
NO954320D0 (no) Lyosfærer omfattende gonadotropin
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
DE59511017D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
HUT77627A (hu) 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények
IL116231A (en) Dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals as thrombin inhibitors
ATE179164T1 (de) Hiv-proteaseinhibitoren
ATE197545T1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
DE59409923D1 (de) Substituierte aminoalkylaminopyridine
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BR0317445A (pt) Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
SE9401596D0 (sv) New compounds
DK0678022T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler, som er anvendelige til behandling af stråleskader
ECSP951621A (es) Nuevas sulfonamidas case ran 4019/132
ATE327235T1 (de) 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen
NO974687L (no) Kondenserte <beta>-carboliner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0799209

Country of ref document: EP